Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - ARQULE INC | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 10, 2014
ARQULE, INC.
(Exact Name of Issuer as Specified in Charter)
|
Delaware
|
000-21429
|
04-3221586
|
||||||||
|
(State or other jurisdiction
|
(Commission File Number)
|
(I.R.S. Employer
|
||||||||
|
of incorporation)
|
Identification No.)
|
|||||||||
|
19 Presidential Way
|
||||
|
Woburn, MA
|
||||
| (Address of principal executive offices) | ||||
|
01801
|
||||
| (Zip code) | ||||
|
(781) 994-0300
|
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Section 8 — Other Events
Item 8.01 Other Events.
On November 10, 2014, ArQule, Inc. (the “Registrant”) issued a press release announcing the top-line results of a single agent trial of tivantinib sponsored by the National Cancer Institute (NCI) in metastatic prostate cancer. The press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit 99.1 Text of press release dated November 10, 2014 reporting clinical status updates.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARQULE, INC.
|
|||
| (Registrant) | |||
| /s/ Peter S. Lawrence | |||
|
Peter S. Lawrence
|
|||
|
President and Chief Operating Officer
|
|||
November
10, 2014
| 3 |